GlassScriptPhysician profile
Mary K Digate
NPI 1356352512
$8,789.33
in general payments reported to CMS, 2019-2025
27 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $1,041 · 2023: $2,053 · 2024: $1,958 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,882 · Travel and Lodging: $661 · Consulting Fee: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,881.60 |
| Travel and Lodging | $660.62 |
| Consulting Fee | $381.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,290.28 | 2021-2025 | Cardiomems, Amplatzer Amulet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,387.17 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $667.35 | 2023-2025 | |
| Scpharmaceuticals INC. | $549.65 | 2023-2025 | |
| Boston Scientific Corporation | $516.33 | 2021-2024 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $388.79 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $350.00 | 2022-2025 | Lokelma, Farxiga, Wainua |
| E.R. Squibb & Sons, L.L.C. | $319.57 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $277.76 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $276.14 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $260.58 | 2022-2025 | Verquvo, Capvaxive |
| Impulse Dynamics (USA) INC. | $235.65 | 2024-2025 | Optimizer |
| Cvrx, INC. | $200.35 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $193.89 | 2022-2024 | Xarelto |
| Bridgebio Pharma, INC. | $177.30 | 2025 | Attruby |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $137.32 | 2022-2023 | Onpattro |
| Abiomed | $105.96 | 2023 | Impella |
| Lexicon Pharmaceuticals, INC. | $103.52 | 2024 | Inpefa |
| Kestra Medical Technology Services, INC. | $68.49 | 2023-2025 | Assure Wcd |
| Novo Nordisk INC | $66.75 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $59.96 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $56.94 | 2024 | |
| Lantheus Medical Imaging, INC. | $25.00 | 2024 | |
| Mannkind Corporation | $24.47 | 2025 | |
| Glaxosmithkline, LLC. | $17.81 | 2025 | Arexvy |
| Kiniksa Pharmaceuticals International, Plc | $16.83 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $15.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Digate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.